CASE STUDY: CAMURUS AND ETHYPHARM
In March 2017, Ethypharm has obtained exclusive distribution rights for episil® oral liquid in France.
episil® oral liquid represents a unique and innovative concept for local treatment of pain associated with oral mucositis (OM), a common side effect of cancer therapies (chemo- and radiotherapy). Clinically demonstrated, episil® has been shown to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours. The product is supplied as a ready-to-use, pocket-sized device helping patients maintain their quality of life while undergoing cancer therapy.
This partnership with Camurus fulfills Ethypharm’s objective of providing effective treatments that address unmet medical needs.
““Ethypharm, with its position in the field of specialised pain care in France, represents a strong addition to our distribution network of episil® in Europe. We look forward to working together to provide patients suffering from oral mucositis with an effective treatment alternative.”
Fredrik Tiberg, President and CEO of Camurus